A Multi Center Phase II Study of 5-Fluorouracil/ Folinic Acid Plus Gemcitabine in Patients With Advanced Pancreatic Cancer.
This open-label, multi center phase II study was conducted to investigate the efficacy and
safety of the combination of 5-Fluorouracil (5-FU)/folinic acid (FA) plus gemcitabine (GFF)
in patients (pts) with advanced pancreatic cancer (APC). We consequently started this study
after completing the phase I trial accomplished by our CONKO- study group.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
helmut oettle, MD
Germany: Ethics Commission
CONKO 002 pilot